- Home
- LXEO vs IPHA Comparison
LXEO vs IPHA Comparison
Compare LXEO & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEO
- IPHA
- Stock Information
- Founded
- LXEO 2017
- IPHA 1999
- Country
- LXEO United States
- IPHA France
- Employees
- LXEO N/A
- IPHA N/A
- Industry
- LXEO
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- LXEO
- IPHA Health Care
- Exchange
- LXEO Nasdaq
- IPHA Nasdaq
- Market Cap
- LXEO 140.6M
- IPHA 160.1M
- IPO Year
- LXEO 2023
- IPHA 2019
- Fundamental
- Price
- LXEO $2.97
- IPHA $2.00
- Analyst Decision
- LXEO Strong Buy
- IPHA Strong Buy
- Analyst Count
- LXEO 5
- IPHA 1
- Target Price
- LXEO $23.80
- IPHA $11.50
- AVG Volume (30 Days)
- LXEO 475.1K
- IPHA 657.4K
- Earning Date
- LXEO 03-18-2025
- IPHA 03-27-2025
- Dividend Yield
- LXEO N/A
- IPHA N/A
- EPS Growth
- LXEO N/A
- IPHA N/A
- EPS
- LXEO N/A
- IPHA N/A
- Revenue
- LXEO N/A
- IPHA $36,202,722.00
- Revenue This Year
- LXEO N/A
- IPHA N/A
- Revenue Next Year
- LXEO N/A
- IPHA $93.37
- P/E Ratio
- LXEO N/A
- IPHA N/A
- Revenue Growth
- LXEO N/A
- IPHA N/A
- 52 Week Low
- LXEO $2.32
- IPHA $1.29
- 52 Week High
- LXEO $19.50
- IPHA $3.51
- Technical
- Relative Strength Index (RSI)
- LXEO 37.57
- IPHA 47.22
- Support Level
- LXEO $2.51
- IPHA $1.99
- Resistance Level
- LXEO $2.95
- IPHA $2.15
- Average True Range (ATR)
- LXEO 0.34
- IPHA 0.13
- MACD
- LXEO 0.07
- IPHA -0.03
- Stochastic Oscillator
- LXEO 40.88
- IPHA 3.53
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a a clinical-stage genetic medicines company dedicated to transforming healthcare by applying pioneering science to fundamentally change how disease is treated. Its pipeline consists of candidates targeting patient populations that place significant burden on society and are most amenable to their genetic medicine approach. The Company is focused on preclinical and clinical stage gene therapies, and specifically on hereditary and acquired diseases of high unmet need which is their only business segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.